IN2012DN02345A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02345A
IN2012DN02345A IN2345DEN2012A IN2012DN02345A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A IN 2345DEN2012 A IN2345DEN2012 A IN 2345DEN2012A IN 2012DN02345 A IN2012DN02345 A IN 2012DN02345A
Authority
IN
India
Prior art keywords
nucleic acid
stranded
methods
tlrs
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Bruce A Sullenger
Jaewoo Lee
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of IN2012DN02345A publication Critical patent/IN2012DN02345A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN2345DEN2012 2009-09-16 2010-09-16 IN2012DN02345A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24309009P 2009-09-16 2009-09-16
PCT/US2010/002516 WO2011034583A2 (en) 2009-09-16 2010-09-16 Inhibition of endosomal toll-like receptor activation

Publications (1)

Publication Number Publication Date
IN2012DN02345A true IN2012DN02345A (enExample) 2015-08-21

Family

ID=43759220

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2345DEN2012 IN2012DN02345A (enExample) 2009-09-16 2010-09-16

Country Status (6)

Country Link
US (3) US9468650B2 (enExample)
EP (1) EP2477641B1 (enExample)
CN (1) CN102639142A (enExample)
CA (1) CA2774460C (enExample)
IN (1) IN2012DN02345A (enExample)
WO (1) WO2011034583A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101702917A (zh) 2007-03-30 2010-05-05 杜克大学 一种调节核酸分子活性的方法
US9468650B2 (en) 2009-09-16 2016-10-18 Duke University Inhibition of endosomal toll-like receptor activation
US9687529B2 (en) 2011-05-05 2017-06-27 Duke University Method of controlling coagulation
WO2014169043A1 (en) * 2013-04-09 2014-10-16 Duke University Anti-inflammatory agents and methods of using the same
WO2015161094A1 (en) 2014-04-16 2015-10-22 Duke University Electrospun cationic nanofibers and methods of making and using the same
WO2017079537A1 (en) 2015-11-04 2017-05-11 Duke University Polycationic polymers for use in treating and detecting cancer
WO2018053427A1 (en) 2016-09-16 2018-03-22 Duke University Von willebrand factor (vwf)-targeting agents and methods of using the same
US12447464B2 (en) 2016-12-22 2025-10-21 Duke University Polycationic microfibers and methods of using the same
EP3601592A4 (en) 2017-03-23 2020-11-25 Duke University ANTIDOTE MEDIA INVERSION OF EXTRACELLULAR APTAMER COLOR
WO2018222484A1 (en) * 2017-05-30 2018-12-06 The Trustees Of Columbia University In The City Of New York Cationic nucleic acid scavenger and uses thereof
EP3678708A4 (en) 2017-09-08 2021-12-08 Duke University NUCLEOLINE TARGETING APTAMERS AND THEIR METHODS FOR USE
WO2021016924A1 (zh) * 2019-07-31 2021-02-04 中山大学 可用于治疗银屑病的阳离子聚合物及颗粒
EP4249913A1 (en) * 2022-03-22 2023-09-27 Centre Hospitalier Universitaire de Nîmes Toll-like-receptor 3 inhibitor for preventing and/or treating disorders in patients with a personal history of venous thromboembolism (vte)

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919761A (en) 1992-08-14 1999-07-06 The Board Of Regents Of The University Of Michigan Peptides for heparin and low molecular weight heparin anticoagulation reversal
US6037329A (en) 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
JP2004508023A (ja) 2000-09-08 2004-03-18 インビトロジェン　コーポレイション 核酸合成の感度および特異性を増強するための化合物および方法
USRE43612E1 (en) 2000-10-10 2012-08-28 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
WO2002053185A2 (en) * 2001-01-05 2002-07-11 Intercell Ag Anti-inflammatory use of polycationic compounds
BR0207905A (pt) 2001-03-08 2004-07-27 Merck Patent Ges Mit Beschroen Protamina modificada com imunogenicidade reduzida
EP2070939B1 (en) 2001-05-25 2014-04-02 Duke University Modulators of pharmacological agents
AUPR604101A0 (en) 2001-06-29 2001-07-26 Unisearch Limited Aptamers
US20050136040A1 (en) 2001-10-11 2005-06-23 Imperial College Innovations Limited Control of gene expression using a complex of an oligonucleotide and a regulatory peptide
US20040063654A1 (en) 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
AU2002368202B2 (en) 2001-11-02 2008-06-05 Insert Therapeutics, Inc Methods and compositions for therapeutic use of RNA interference
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
WO2004032862A2 (en) 2002-10-09 2004-04-22 Insert Therapeutics, Inc. Cyclodextrin-based materials, compositions and uses related thereto
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
US20050136430A1 (en) 2003-07-15 2005-06-23 California Institute Of Technology Inhibitor nucleic acids
KR101185050B1 (ko) 2004-04-22 2012-10-04 레가도 바이오사이언스, 인코포레이티드 응고 인자의 개선된 모듈레이터
US8080245B2 (en) * 2004-08-04 2011-12-20 University Of Massachusetts Anti-pathogen immunoadhesins
GB0422877D0 (en) 2004-10-14 2004-11-17 Univ Glasgow Bioactive polymers
ATE541928T1 (de) 2005-03-31 2012-02-15 Calando Pharmaceuticals Inc Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
US7611835B2 (en) 2005-09-30 2009-11-03 Battelle Memorial Institute Process for preparing multilayer enzyme coating on a fiber
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
WO2007140000A2 (en) 2006-05-26 2007-12-06 Regado Biosciences, Inc. Administration of the reg1 anticoagulation system
EP2035041B1 (en) * 2006-06-30 2020-01-08 Syntab Therapeutics GmbH Conjugates for innate immunotherapy of cancer
WO2008066621A2 (en) 2006-10-19 2008-06-05 Duke University Reversible platelet inhibition
WO2008063157A2 (en) * 2006-10-25 2008-05-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A nanoparticle-based anticoagulant
AU2008216669B2 (en) * 2007-02-15 2013-12-12 Mannkind Corporation A method for enhancing T cell response
CN101702917A (zh) * 2007-03-30 2010-05-05 杜克大学 一种调节核酸分子活性的方法
KR20100082840A (ko) 2007-09-27 2010-07-20 에스체아 히기에너 프로덕츠 악티에볼라그 클레이결합된 폴리머 겔
WO2009064767A2 (en) 2007-11-12 2009-05-22 Massachusetts Institute Of Technology Bactericidal nanofibers, and methods of use thereof
WO2010020008A1 (en) 2008-08-22 2010-02-25 Polymers Crc Limited Polymer coatings
US8992991B2 (en) 2009-05-15 2015-03-31 The Johns Hopkins University Multicomponent degradable cationic polymers
US9468650B2 (en) 2009-09-16 2016-10-18 Duke University Inhibition of endosomal toll-like receptor activation
WO2012088059A2 (en) 2010-12-20 2012-06-28 Virginia Commonwealth University A facile method for crosslinking and incorporating bioactive molecules into electrospun fiber scaffolds
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance

Also Published As

Publication number Publication date
US9468650B2 (en) 2016-10-18
US20230248805A1 (en) 2023-08-10
US20170095503A1 (en) 2017-04-06
EP2477641A4 (en) 2013-08-07
WO2011034583A3 (en) 2011-10-06
CA2774460C (en) 2016-08-09
US11617779B2 (en) 2023-04-04
CN102639142A (zh) 2012-08-15
EP2477641B1 (en) 2024-03-27
EP2477641A2 (en) 2012-07-25
CA2774460A1 (en) 2011-03-24
US20120183564A1 (en) 2012-07-19
WO2011034583A2 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
WO2011034583A3 (en) Inhibition of endosomal toll-like receptor activation
WO2020198509A3 (en) Modified oligonucleotides with increased stability
EP2569453A4 (en) Nucleic Acid ISOLATION METHOD
BR112014005205A2 (pt) métodos para etiquetar bibliotecas codificadas com dna
WO2007136736A3 (en) Methods for nucleic acid sorting and synthesis
MX2010002113A (es) Metodos para detectar oligonucleotidos.
WO2006029258A3 (en) Aptamer medicinal chemistry
WO2009012363A3 (en) Nucleotides and aptamers containing boronic acid groups having biased binding to glycosylated proteins, and uses thereof
IL190501A0 (en) Multicomponent nucleic acid enzymes and methods for their use
WO2010026488A3 (en) Methods and kits for nucleic acid sequencing
EP1994142A4 (en) METHOD AND COMPOSITIONS FOR FAST ISOLATION OF SMALL RNA MOLECULES
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
IN2014DN03463A (enExample)
WO2008063203A3 (en) Compositions and methods for efficient gene silencing in plants
WO2008061537A3 (en) Oligonucleotides for modulating target rna activity
WO2008151631A3 (en) Use of short oligonucleotides for reagent redundancy experiments in rna functional analysis
WO2005097993A3 (en) Immunostimulatory viral rna oligonucleotides
WO2010141511A3 (en) Polynucleotides for multivalent rna interference, compositions and methods of use thereof
AR067135A1 (es) Metodos para aislar arn de fragmento largo de muestras fijas
ATE534737T1 (de) Gezielte abgabe von sirna
AU2014219019A8 (en) Short interfering nucleic acid (siNA) molecules containing a 2' internucleoside linkage
EE200200051A (et) Tenastsiin C nukleiinhappelised ligandid
BR112014021993A2 (pt) detecção da variação de nucleotídeo em sequência de ácido nucleico alvo através de ensaio de clivagem e extensão de pto
WO2011056073A3 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
IN2014CN03921A (enExample)